Pharming Group NV - Company Profile
Powered by
All the data and insights you need on Pharming Group NV in one report.
- Save hours of research time and resources with
our up-to-date Pharming Group NV Strategy Report
- Understand Pharming Group NV position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Pharming Group NV (Pharming) develops precision medicines and innovative protein replacement therapies for the treatment of rare diseases and unmet medical needs. The company’s marketed product includes, Ruconest (conestat alfa), a recombinant human C1 inhibitor is used for the treatment of acute hereditary angioedema (HAE) and has been approved in the US, the UK, Europe, Israel, and South Korea. Its product pipeline consists of leniolisib for treatment of activated phosphoinositide 3-kinase delta syndrome (APDS); α-Glucosidase for the treatment of Pompe disease. The company markets its products through own sales force and network of distributors and partners. Pharming is headquartered in Leiden, the Netherlands.
Pharming Group NV premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Ruconest- Acute Hereditary Angioedema (HAE) | Ruconest |
Joenja- APDS | Joenja |
Pipeline | |
XYZ | |
XYZ | |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2023 | Plans/Strategy | In December, the company announced its plans to develop leniolisib for additional primary immunodeficiencies. |
2023 | Contracts/Agreements | In June, the company entered into a definitive agreement with Novartis Pharma to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to Novartis for a pre-agreed, one-time payment of approximately US$21.1 million. |
2023 | Regulatory Approval | In March, the company secured an approval from the US Food and Drug Administration for Joenja (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adult and pediatric patients 12 years of age and older. |
Competitor Comparison
Key Parameters | Pharming Group NV | Takeda Pharmaceutical Co Ltd | BioMarin Pharmaceutical Inc | Argenx SE | BioCryst Pharmaceuticals Inc |
---|---|---|---|---|---|
Headquarters | Netherlands | Japan | United States of America | Netherlands | United States of America |
City | Leiden | Chuo-Ku | Novato | Amsterdam | Durham |
State/Province | - | Tokyo | California | Noord-Holland | North Carolina |
No. of Employees | 415 | 49,095 | 3,401 | 1,148 | 536 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Richard Peters | Chairman | Executive Board | 2023 | - |
Sijmen De Vries, M.D. | Director; Chief Executive Officer | Executive Board | - | 63 |
Jeroen Wakkerman | Chief Financial Officer | Senior Management | 2020 | 53 |
Mireille Sanders | Chief Operating Officer | Senior Management | 2020 | 54 |
Daniela Dos Anjos Hanova | Chief People Officer | Senior Management | 2023 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer